120 related articles for article (PubMed ID: 37605410)
21. [Screening of Differential Expression Autophagy Genes Related to the Prognosis of Diffuse Large B-Cell Lymphoma and Establishment of an Autophagy Model].
Zhang JD; Zhang HM; Lu D; Wang ZN; Chen HR; Lu XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1101-1108. PubMed ID: 35981368
[TBL] [Abstract][Full Text] [Related]
22. [Based on CT radiomics model for predicting the response to first-line chemotherapy of diffuse large B-cell lymphoma].
Yin MX; Su QN; Song X; Zhang JX
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):438-444. PubMed ID: 37188630
[No Abstract] [Full Text] [Related]
23. Exploring the shared gene signatures of smoking-related osteoporosis and chronic obstructive pulmonary disease using machine learning algorithms.
Wang H; Li S; Chen B; Wu M; Yin H; Shao Y; Wang J
Front Mol Biosci; 2023; 10():1204031. PubMed ID: 37251077
[No Abstract] [Full Text] [Related]
24. Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma.
Charwudzi A; Meng Y; Hu L; Ding C; Pu L; Li Q; Xu M; Zhai Z; Xiong S
PeerJ; 2021; 9():e12394. PubMed ID: 34760386
[TBL] [Abstract][Full Text] [Related]
25. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
26. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
27. Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of Schisandra Chinensis Mixture on diabetic nephropathy.
Ma Y; Deng Y; Li N; Dong A; Li H; Chen S; Zhang S; Zhang M
J Ethnopharmacol; 2023 Feb; 302(Pt A):115768. PubMed ID: 36280016
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking.
Zhao Q; Huang S; Yang L; Chen T; Qiu X; Huang R; Dong L; Liu W
Technol Health Care; 2024 Feb; ():. PubMed ID: 38517810
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma.
Liu C; Liu L
Front Genet; 2022; 13():1037716. PubMed ID: 36313435
[No Abstract] [Full Text] [Related]
30. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
31. Identification of
Xiang X; Gao LM; Zhang Y; Tang Y; Zhao S; Liu W; Ye Y; Zhang W
Front Genet; 2022; 13():849422. PubMed ID: 35711924
[TBL] [Abstract][Full Text] [Related]
32. miRNA-Gene Interaction Network Construction Strategy to Discern Promising Traditional Chinese Medicine against Osteoporosis.
Li L; Ayiding X; Han R
Biomed Res Int; 2022; 2022():9093614. PubMed ID: 35757478
[TBL] [Abstract][Full Text] [Related]
33. Identification of the Mechanism of Matrine Combined with Glycyrrhizin for Hepatocellular Carcinoma Treatment through Network Pharmacology and Bioinformatics Analysis.
Han T; Liu Y; Chen Y; Chen T; Li Y; Li Q; Zhao M
Oxid Med Cell Longev; 2022; 2022():2663758. PubMed ID: 36193082
[TBL] [Abstract][Full Text] [Related]
34. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Zheng W; Lin Q; Issah MA; Liao Z; Shen J
BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
[TBL] [Abstract][Full Text] [Related]
35. Identification of potential key genes associated with diffuse large B-cell lymphoma based on microarray gene expression profiling.
Luo X; Shi F; Qiu H; Tong Y; Gao X
Neoplasma; 2017; 64(6):824-833. PubMed ID: 28895406
[TBL] [Abstract][Full Text] [Related]
36. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms.
Yuan Q; Ren J; Wang Z; Ji L; Deng D; Shang D
Front Genet; 2021; 12():692953. PubMed ID: 34490033
[No Abstract] [Full Text] [Related]
37. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
[TBL] [Abstract][Full Text] [Related]
38. KIF23 is a potential biomarker of diffuse large B cell lymphoma: Analysis based on bioinformatics and immunohistochemistry.
Gong Y; Zhou L; Ding L; Zhao J; Wang Z; Ren G; Zhang J; Mao Z; Zhou R
Medicine (Baltimore); 2022 Jun; 101(24):e29312. PubMed ID: 35713434
[TBL] [Abstract][Full Text] [Related]
39. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
Zhang Q; Zhu Z; Guan J; Zheng C
Front Oncol; 2022; 12():904614. PubMed ID: 35814424
[TBL] [Abstract][Full Text] [Related]
40. A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.
Xu H; Li Y; Jiang Y; Wang J; Sun H; Wu W; Lv Y; Liu S; Zhai Y; Tian L; Li L; Zhao Z
Front Genet; 2022; 13():827840. PubMed ID: 35774514
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
